Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)
Sponsor: EIP Pharma Inc
Terminated
Due to the long delay because of COVID-19 and results from another study suggesting a higher dose may be more beneficial, EIP Pharma decided on October 15th, 2020, to end the trial prematurely.
Other Huntington Disease trials with similar outcome
A PHASE2 clinical study on Huntington Disease, this trial is terminated or withdrawn. The trial is conducted by EIP Pharma Inc and has accumulated 8 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — May 2022 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EIP Pharma Inc
- Voisin Consulting, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .